| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3274363 | Médecine des Maladies Métaboliques | 2014 | 12 Pages |
Abstract
This review presents exenatide prolonged-release (Bydureon®) main pharmacokinetics and pharmacokinetics properties and results from randomized clinical trials, a GLP-1R agonist approved for T2D treatment and marketed in the US and approved in Europe where it is available in some countries and expected to be available in France.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
B. Guerci, J.-P. Sauvanet,